Cargando…

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Transforming growth factor-beta (TGF-β) signaling plays an important role in the fetal development of cardiovascular organs and in the repair mechanisms of the heart. Hence, inhibitors of the TGF-β signaling pathway require a careful identification of a safe therapeutic window and a comprehensive mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovacs, Richard J., Maldonado, Giuliana, Azaro, Analia, Fernández, Maria S., Romero, Federico L., Sepulveda-Sánchez, Juan M., Corretti, Mary, Carducci, Michael, Dolan, Melda, Gueorguieva, Ivelina, Cleverly, Ann L., Pillay, N. Sokalingum, Baselga, Jose, Lahn, Michael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575352/ https://www.ncbi.nlm.nih.gov/pubmed/25488804 http://dx.doi.org/10.1007/s12012-014-9297-4

Ejemplares similares

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
por: Rodón, Jordi, et al.
Publicado: (2014)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Polymeric Nano-Micelles as Novel Cargo-Carriers for LY2157299 Liver Cancer Cells Delivery
por: Hanafy, Nemany Abdelhamid Nemany, et al.
Publicado: (2018)

Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl(4)-Induced Liver Fibrosis in Rats
por: Panzarini, Elisa, et al.
Publicado: (2022)

Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats
por: Liu, X., et al.
Publicado: (2016)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
Publicado: (2014)

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
por: Wick, Antje, et al.
Publicado: (2020)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
por: Downing, AnnCatherine M, et al.
Publicado: (2014)

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
por: O’Brien, Peter J, et al.
Publicado: (2008)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
por: Adams, David H., et al.
Publicado: (2014)

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics
por: Wacheck, Volker, et al.
Publicado: (2011)

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients
por: Saleem, Azeem, et al.
Publicado: (2011)

Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016)

Developmental and communicative interrelations of Ly123 and Ly1 cell sets
Publicado: (1980)

Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
por: Andreidesz, Kitti, et al.
Publicado: (2021)

Neces-SARI-ly?
por: Martin-Loeches, Ignacio, et al.
Publicado: (2016)

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

Running Mad-ly into mitosis
por: LeBrasseur, Nicole
Publicado: (2004)

Virulence profile: Hinh Ly
por: Ly, Hinh
Publicado: (2016)

LY6K depletion modulates TGF‐β and EGF signaling
por: Park, Sujeong, et al.
Publicado: (2023)

Comparison of Mouse Ly5(a) and Ly5(b) Leucocyte Common Antigen Alleles
por: Zebedee, Suzanne L., et al.
Publicado: (1991)

Secretion of Ia antigens by a subpopulation of T cells which are Ly-1+, Ly-2-, and Ia-
Publicado: (1976)

CCR2 Deficiency Impairs Ly6C(lo) and Ly6C(hi) Monocyte Responses in Orientia tsutsugamushi Infection
por: Petermann, Michael, et al.
Publicado: (2021)

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
por: Simon, George R., et al.
Publicado: (2011)

Expression of Ly 1, Ly 2, Thy 1, and TL differentiation antigens on mouse T-cell tumors
Publicado: (1978)

Occurrences and Functions of Ly6C(hi) and Ly6C(lo) Macrophages in Health and Disease
por: Li, Yuan-hui, et al.
Publicado: (2022)

Models of Ly$\alpha$ forest clouds
por: Charlton, J C
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_b84p5eki2fjupuovih403tlnep